Stock Scorecard



Stock Summary for Illumina Inc (ILMN) - $144.81 as of 1/30/2026 8:05:09 PM EST

Total Score

5 out of 30

Safety Score

41 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ILMN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ILMN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ILMN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ILMN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ILMN (41 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 6
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for ILMN

Boulder biotech SomaLogic acquired in deal worth up to $425M 1/30/2026 10:00:00 PM
Standard BioTools Completes Sale of SomaLogic to Illumina 1/30/2026 3:01:00 PM
Standard BioTools Completes Sale of SomaLogic to Illumina 1/30/2026 2:01:00 PM
SomaLogic Partnership Resource Hub 1/30/2026 2:01:00 PM
Illumina bets $350M on proteins to help speed drug discovery 1/30/2026 2:01:00 PM
Standard BioTools completes sale of SomaLogic to Illumina for $350 million 1/30/2026 2:01:00 PM
Illumina completes acquisition of SomaLogic 1/30/2026 2:01:00 PM
The Truth About Illumina Inc.: Is This DNA Giant Still Worth Your Money or Is the Hype Over? 1/29/2026 10:03:00 PM
New Horizons in Microfluidic Market Booming with Rapid Growth Through 2033 |Agilent Technologies, Inc., Illumina, Inc. 1/29/2026 8:59:00 AM
Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products 1/28/2026 9:00:00 AM

Financial Details for ILMN

Company Overview

Ticker ILMN
Company Name Illumina Inc
Country N/A
Description Illumina, Inc. is a leading global biotechnology company based in San Diego, California, known for its groundbreaking innovations in genomic analysis technologies since its founding in 1998. The company specializes in sequencing, genotyping, and gene expression solutions, serving a broad range of sectors including research, clinical diagnostics, and agricultural genomics. Illumina's unwavering commitment to innovation has established it as a leader in the genomics field, driving significant advancements in genetic research and diagnostics that enhance health outcomes worldwide. By enabling personalized medicine, Illumina plays a pivotal role in shaping the future of healthcare.
Sector Name HEALTHCARE
Industry Name DIAGNOSTICS & RESEARCH
Most Recent Quarter 9/30/2025
Next Earnings Date 2/5/2026

Stock Price History

Last Day Price 144.81
Price 4 Years Ago 196.69
Last Day Price Updated 1/30/2026 8:05:09 PM EST
Last Day Volume 2,477,122
Average Daily Volume 1,804,348
52-Week High 155.53
52-Week Low 68.70
Last Price to 52 Week Low 110.79%

Valuation Measures

Trailing PE N/A
Industry PE 42.12
Sector PE 95.54
5-Year Average PE 79.38
Free Cash Flow Ratio 21.08
Industry Free Cash Flow Ratio 55.27
Sector Free Cash Flow Ratio 26.23
Current Ratio Most Recent Quarter 1.43
Total Cash Per Share 6.87
Book Value Per Share Most Recent Quarter 15.56
Price to Book Ratio 9.64
Industry Price to Book Ratio 10.13
Sector Price to Book Ratio 22.01
Price to Sales Ratio Twelve Trailing Months 5.39
Industry Price to Sales Ratio Twelve Trailing Months 4.86
Sector Price to Sales Ratio Twelve Trailing Months 18.97
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 152,800,000
Market Capitalization 22,126,968,000
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 2.17%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -77.80%
Annual Earnings Growth -5.34%
Reported EPS 12 Trailing Months 4.46
Reported EPS Past Year 3.50
Reported EPS Prior Year 2.45
Net Income Twelve Trailing Months 703,000,000
Net Income Past Year -1,223,000,000
Net Income Prior Year -1,161,000,000
Quarterly Revenue Growth YOY 0.40%
5-Year Revenue Growth 4.29%
Operating Margin Twelve Trailing Months 21.40%

Balance Sheet

Total Cash Most Recent Quarter 1,050,000,000
Total Cash Past Year 1,127,000,000
Total Cash Prior Year 1,048,000,000
Net Cash Position Most Recent Quarter 56,000,000
Net Cash Position Past Year -363,000,000
Long Term Debt Past Year 1,490,000,000
Long Term Debt Prior Year 1,489,000,000
Total Debt Most Recent Quarter 994,000,000
Equity to Debt Ratio Past Year 0.61
Equity to Debt Ratio Most Recent Quarter 0.71
Total Stockholder Equity Past Year 2,373,000,000
Total Stockholder Equity Prior Year 5,745,000,000
Total Stockholder Equity Most Recent Quarter 2,381,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 1,007,000,000
Free Cash Flow Per Share Twelve Trailing Months 6.59
Free Cash Flow Past Year 709,000,000
Free Cash Flow Prior Year 283,000,000

Options

Put/Call Ratio 0.32
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 1.41
RSI 0.00
50-Day SMA 0.00
150-Day SMA 129.27
200-Day SMA 151.16

System

Modified 1/29/2026 1:09:56 AM EST